SCOL Stock Overview
Scandion Oncology A/S, a clinical-stage biotechnology company, discovers and develops medicines for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Scandion Oncology A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr1.39 |
| 52 Week High | kr5.64 |
| 52 Week Low | kr0.90 |
| Beta | 1.28 |
| 1 Month Change | -30.15% |
| 3 Month Change | -69.72% |
| 1 Year Change | -23.12% |
| 3 Year Change | -93.14% |
| 5 Year Change | n/a |
| Change since IPO | -86.43% |
Recent News & Updates
Recent updates
We Think Scandion Oncology (STO:SCOL) Needs To Drive Business Growth Carefully
Aug 02
Companies Like Scandion Oncology (STO:SCOL) Are In A Position To Invest In Growth
Feb 01Here's Why We're Not Too Worried About Scandion Oncology's (STO:SCOL) Cash Burn Situation
May 26We're Hopeful That Scandion Oncology (NGM:SCOL) Will Use Its Cash Wisely
Jan 06
Shareholder Returns
| SCOL | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -42.6% | -0.06% | 0.9% |
| 1Y | -23.1% | -5.3% | 10.3% |
Price Volatility
| SCOL volatility | |
|---|---|
| SCOL Average Weekly Movement | 17.1% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: SCOL's share price has been volatile over the past 3 months.
Volatility Over Time: SCOL's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 4 | Francois Martelet | www.scandiononcology.com |
Scandion Oncology A/S, a clinical-stage biotechnology company, discovers and develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase II clinical trial for the treatment of colorectal cancer; and in Phase I clinical trial for treating pancreatic cancer, as well as in preclinical studies for other cancer indications. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV.
Scandion Oncology A/S Fundamentals Summary
| SCOL fundamental statistics | |
|---|---|
| Market cap | kr56.58m |
| Earnings (TTM) | -kr61.20m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs SCOL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SCOL income statement (TTM) | |
|---|---|
| Revenue | kr.0 |
| Cost of Revenue | kr.0 |
| Gross Profit | kr.0 |
| Other Expenses | kr.39.20m |
| Earnings | -kr.39.20m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 22, 2024
| Earnings per share (EPS) | -0.96 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SCOL perform over the long term?
See historical performance and comparison